Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial.
Dianna QuanLaura ObiciJohn L BerkYukio AndoEmre AldincMatthew T WhiteDavid AdamsPublished in: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis (2022)
Patisiran treatment improved neurologic function and QOL across a wide range of baseline polyneuropathy severities versus placebo. Timing of treatment initiation in patients with ATTRv amyloidosis remains critical for the preservation of function.(ClinicalTrials.gov number, NCT01960348).